Clinical trials under way
Promising candidates for neuroprotection in glaucoma that target RGC viability are being investigated in clinical trials. Two studies are under way at Stanford University, and Dr. Goldberg is the principal investigator for the trials.
Topical treatment with recombinant human nerve growth factor (Dompé Farmaceutici) is being evaluated in a phase I single center, double-masked, placebo-controlled study is being conducted at Stanford and includes 60 patients with primary open-angle glaucoma. Eligible patients had progressive disease despite maximal therapy or stable IOP but diminished vision. The trial has a 32-week duration.
Stanford is also participating in a phase II multicenter, single-masked randomized trial of NT-501 encapsulated cell therapy (Neurotech), an intravitreal device that secretes ciliary neurotrophic factor (CNTF). Other participating sites are Glaucoma Associates of Texas, Dallas, Columbia University, New York, and New York University, New York.
Enrolled patients received NT-501 or underwent sham surgery. The primary outcome analysis will be performed at 6 months and follow-up will continue to 2 years.
Jeffrey L. Goldberg, MD, PhD
E: [email protected]
This article was adapted from Dr. Goldberg's presentation during Glaucoma Subspecialty Day at the 2017 meeting of the American Academy of Ophthalmology. Dr. Goldberg has no financial interests in the products discussed.